X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES TORRENT PHARMA VENUS REMEDIES/
TORRENT PHARMA
 
P/E (TTM) x -881.7 25.8 - View Chart
P/BV x 0.3 6.3 4.1% View Chart
Dividend Yield % 0.0 3.2 -  

Financials

 VENUS REMEDIES   TORRENT PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
TORRENT PHARMA
Mar-16
VENUS REMEDIES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs2181,720 12.7%   
Low Rs821,134 7.2%   
Sales per share (Unadj.) Rs365.6394.5 92.7%  
Earnings per share (Unadj.) Rs1.5101.8 1.5%  
Cash flow per share (Unadj.) Rs37.9116.3 32.6%  
Dividends per share (Unadj.) Rs040.00 0.0%  
Dividend yield (eoy) %02.8 0.0%  
Book value per share (Unadj.) Rs382.5200.3 191.0%  
Shares outstanding (eoy) m11.44169.22 6.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.6 11.3%   
Avg P/E ratio x101.014.0 720.3%  
P/CF ratio (eoy) x4.012.3 32.3%  
Price / Book Value ratio x0.47.1 5.5%  
Dividend payout %039.3 0.0%   
Avg Mkt Cap Rs m1,717241,435 0.7%   
No. of employees `0001.010.9 9.4%   
Total wages/salary Rs m3248,559 3.8%   
Avg. sales/employee Rs Th4,100.76,129.6 66.9%   
Avg. wages/employee Rs Th318.0785.8 40.5%   
Avg. net profit/employee Rs Th16.71,581.3 1.1%   
INCOME DATA
Net Sales Rs m4,18366,764 6.3%  
Other income Rs m202,156 0.9%   
Total revenues Rs m4,20368,920 6.1%   
Gross profit Rs m81227,204 3.0%  
Depreciation Rs m4172,461 16.9%   
Interest Rs m3801,859 20.4%   
Profit before tax Rs m3525,041 0.1%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-1,403 0.0%   
Tax Rs m186,414 0.3%   
Profit after tax Rs m1717,224 0.1%  
Gross profit margin %19.440.7 47.6%  
Effective tax rate %51.625.6 201.3%   
Net profit margin %0.425.8 1.6%  
BALANCE SHEET DATA
Current assets Rs m2,77146,622 5.9%   
Current liabilities Rs m1,93132,843 5.9%   
Net working cap to sales %20.120.6 97.2%  
Current ratio x1.41.4 101.1%  
Inventory Days Days12574 168.4%  
Debtors Days Days5479 68.0%  
Net fixed assets Rs m5,32839,029 13.7%   
Share capital Rs m114846 13.5%   
"Free" reserves Rs m4,17731,400 13.3%   
Net worth Rs m4,37633,890 12.9%   
Long term debt Rs m1,91118,637 10.3%   
Total assets Rs m8,42890,136 9.4%  
Interest coverage x1.114.5 7.5%   
Debt to equity ratio x0.40.5 79.4%  
Sales to assets ratio x0.50.7 67.0%   
Return on assets %4.721.2 22.2%  
Return on equity %0.450.8 0.8%  
Return on capital %6.648.5 13.6%  
Exports to sales %043.3 0.0%   
Imports to sales %20.56.9 298.9%   
Exports (fob) Rs mNA28,934 0.0%   
Imports (cif) Rs m8584,584 18.7%   
Fx inflow Rs m029,185 0.0%   
Fx outflow Rs m8586,021 14.3%   
Net fx Rs m-85823,165 -3.7%   
CASH FLOW
From Operations Rs m46927,132 1.7%  
From Investments Rs m29-7,014 -0.4%  
From Financial Activity Rs m-464-14,352 3.2%  
Net Cashflow Rs m355,767 0.6%  

Share Holding

Indian Promoters % 32.9 71.5 45.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 7.0 2.6%  
FIIs % 0.6 12.6 4.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 8.8 754.5%  
Shareholders   20,121 26,511 75.9%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

World Stocks Mixed as Global Market Rally Loses Momentum(RoundUp)

Global financial markets ended the week on a mixed note. In the US, the Dow industrials ended the week down 0.4%, while the S&P 500 declined 0.1%.

Related Views on News

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

More Views on News

Most Popular

The Real Brave-hearts are Those Who Still Have Deposits in IDBI Bank(Vivek Kaul's Diary)

Nov 6, 2017

It makes no sense to continue banking with this bank.

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Large cap funds are more liquid(The Honest Truth)

Nov 6, 2017

Is the dangerous illiquidity risk in small-cap and mid-cap funds common to large-cap funds too?

You're Lucky You Missed Out on that IPO...(Smart Contrarian)

Nov 8, 2017

Here's how to profit from upcoming IPOs.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 17, 2017 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS